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Abstract: The purpose of the present study was to formulate effective and controlled release 
albendazole liposomal formulations. Albendazole, a hydrophobic drug used for the treatment of 
hydatid cysts, was encapsulated in nanosize liposomes. Rapid evaporation method was used for 
the preparation of albendazole-encapsulated conventional and PEGylated liposomes consisting 
of egg phosphatidylcholine (PC) and cholesterol (CH) in the molar ratios of (6:4) and PC:CH:
polyethylene glycol (PEG) (5:4:1), respectively. In this study, PEGylated and conventional 
liposomes containing albendazole were prepared and their characteristics, such as particle size, 
encapsulation efficiency, and in vitro drug release were investigated. The drug encapsulation 
efficiency of PEGylated and conventional liposomes was 81% and 72%, respectively. The 
biophysical characterization of both conventional and PEG-coated liposomes were done by 
transmission electron microscopy and UV-vis spectrophotometry. Efforts were made to study 
in vitro release of albendazole. The drug release rate showed decrease in albendazole release in 
descending order: free albendazole, albendazole-loaded conventional liposomes, and least with 
albendazole-loaded PEG-liposomes. Biologically relevant vesicles were prepared and in vitro 
release of liposome-entrapped albendazole was determined.
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Introduction
Liposomes are vesicles of varying size consisting of a spherical lipid bilayer and 
an aqueous inner compartment that are generated in vitro. In 1965, Bangham and 
colleagues first used a liposomal structure as a model to study the effect of narcotics 
on lipid bilayer membranes.1 These are useful in terms of biocompatibility, biodegrad-
ability, and low toxicity, and can control biodistribution by changing the size, lipid 
composition, and physical characteristics.2–4 Furthermore, liposomes can entrap both 
hydrophobic and hydrophilic drugs and are able to continuously release the entrapped 
substrate,5 thus being useful drug carriers.6–8 Polyethylene glycol (PEG) modification 
on the liposomal surface is known to be effective in preventing their uptake by the 
reticuloendothelial system (RES). Incorporation of PEG-lipids causes the liposome 
to remain in the blood circulation for extended periods of time (ie, t½  40 hours) 
and distribute through an organism relatively evenly with most of the dose remaining 
in the central compartment (ie, the blood) and only 10% to 15% of the dose being 
delivered to the liver.9–11 Long-circulating, PEGylated liposomes provide an attractive 
platform to improve the therapeutic index of a variety of drugs. A number of drugs 
have already been successfully encapsulated in liposomes, from antibacterials12 and 
interferons13 to antitumor drugs such as doxorubicin.14International Journal of Nanomedicine 2010:5 102
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Albendazole  (ABZ),  methyl  [5-(propylthio)-
1-H-benzimidazol-2yl] carbamate, is a benzimidazol deriva-
tive and it is effective in the treatment of echinococcosis, 
hydatid cysts, and neurocysticercosis. The therapeutic response 
of albendazole (20% to 50%) in cases of echinococcosis is 
variable and difficult to predict.15,16 Albendazole’s poor intes-
tinal absorption (5%) (due to its low aqueous solubility) is 
probably a major determinant of the variable response rate.17 
In vitro and in vivo antifungal activity of albendazole was 
studied by Hardin and colleagues.18 Albenza® (albendazole) 
is an orally administered broad-spectrum anthelmintic and 
has been used for hydatid disease with promising results.19–21 
Repeated dose therapy is the only treatment for this disease 
and a course of albendazole for prescribed period has to be 
completed by the patients. Therefore, preparation of drug 
formulations that facilitate controlled release of the drug to 
the target site is an important goal.
The objective of the present study was to prepare alben-
dazole-encapsulated liposomal formulations. A comparison 
study was performed between conventional and PEG-coated 
or stealth liposomes to evaluate the in vitro performance of 
these formulations. Characterization of the prepared lipo-
somes regarding physical morphology, particle size, and 
in vitro drug release was performed. A stability study was 
performed to investigate the release of drug from liposomes 
during storage.
Materials and methods
Materials
Albendazole was purchased from Cipla Pharma Co. (Mumbai, 
India). Egg phosphatidylcholine (PC), cholesterol (CH), and 
PEG were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). All the chemicals and solvents used in the study 
were of analytical and high-pressure liquid chromatography 
(HPLC) grade and purchased from Sigma Chemicals Co. 
(St. Louis, MO, USA), Himedia Laboratories Ltd. (Mumbai, 
India), Bangalore Genei (Bengalaru, India), and deionized 
water was used throughout the experiments.
Methods
Preparation of conventional and stealth liposomes
The PC liposomes were prepared using a rapid evaporation 
method.22 The composition of the conventional liposomes pre-
pared was albendazole-encapsulated PC:CH taken in the ratio of 
6:4 and dissolved in a chloroform:methanol mixture (1:1, V/V). 
The PEG-liposomes were prepared by mixing albendazole-
encapsulated PC:CH:PEG-PC in the ratio of 5:4:1. Lipids 
were dissolved in 50 mL of isopropyl methanol:chloroform 
solution taken in the ratio of 1:1. Albendazole was dissolved in 
the same solvent mixture and added to the lipid solution. The 
mixture was sonicated for four minutes in a bath-type sonicator 
(Soniprep 150; MSE, Van Nuys, CA, USA). The organic solvent 
was then removed using rotary evaporator at 40°C and 50 rpm 
(Metrex, Delhi, India). In the case of albendazole, the resulting 
thin lipid film was slowly hydrated using bicarbonate buffer 
(pH 9.0). The process of hydration was carried out by rotation 
at a low speed at 55°C in a rotary evaporator under atmospheric 
pressure followed by hand shaking for 15 minutes at 55°C in a 
thermostatically controlled water bath. The resulting liposomal 
dispersion was left to mature overnight at 4°C. All the above 
steps were performed under aseptic conditions. All glassware 
was sterilized by autoclaving, and the entire procedure was 
performed in a laminar flow hood (Lab Companion; JEIO 
Tech, Seoul, Korea).
Free drug separation
Free unentrapped drug was separated from albendazole-
encapsulated conventional and stealth liposomes by cen-
trifugation at 20,000 g for 1 hour at 4°C in a refrigerated 
centrifuge (model 3–18 K; Sigma-Aldrich). The pellets 
formed were washed twice with 10 mL bicarbonate buffer 
(pH 9.0) and recentrifuged again for 1 hour.
Determination of encapsulation efficiency
The percentage of drug encapsulated was determined after 
lysis of the prepared liposomes with absolute alcohol and 
sonication for 10 minutes.23 The concentration of albendazole 
in absolute alcohol was determined spectrophotometrically 
at 265 nm using a UV-visible spectrophotometer (model 
UV-1700 (E); Schimadzu, Kyoto, Japan) in triplicate. The 
encapsulation efficiency expressed as entrapment percentage 
was calculated through the following relationship:24
	Encapsulation efficiency
Totaldrug freedrug
Totaldrug
% . =
−
×100
	
characterization of albendazole iposomes
Liposomes vary in size from 20 nm to several µm. Using a 
transmission electron microscope, size of conventional and 
PEG-coated liposomes were determined. The liposomes were 
photographed at an original magnification ×1000 to ×25000, 
using a transmission electron microscope (TEM; JEOL, 
Tokyo, Japan).
stability study
The stability of the albendazole-encapsulated PEG-liposomes 
was evaluated after storage at −20°C, +4°C and 25°C International Journal of Nanomedicine 2010:5 103
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for three months. The particle size distribution and drug 
encapsulation efficiency of the samples were determined as 
a function of the storage time.
In vitro drug release studies
Drug release from liposomes was studied using a dialysis 
method. Dialysis bags were soaked before use in distilled 
water at room temperature for 12 hours to remove the 
preservative, followed by rinsing thoroughly in distilled 
water. In vitro release of albendazole from liposomes was 
conducted by dialysis in a dialysis sac (12,000 MW cut 
off; Sigma-Aldrich) with 150 mL of phosphate-buffered 
saline (PBS; pH 5.6) containing 7% (V/V) propylene glycol 
and 25% (V/V) methanol at 37°C following the method 
published previously.25 Three sacs were prepared containing 
free albendazole as control, albendazole in conventional 
liposomes, and albendazole in PEGcoated liposomes.
Liposomal concentrate (equivalent to 2 mg albendazole) 
dispersed in 1 mL of bicarbonate buffer (pH 9) was placed in 
a dialysis bag. Control bags were prepared and tested along 
with the liposomal dispersions. Each control bag contained 
2 mg albendazole. Two ends of the dialysis sac were tightly 
bound with threads. The sac was hung inside a conical flask 
with the help of a glass rod so that the portion of the dialysis 
sac with the formulation dipped into the buffer solution. The 
flask was kept on a magnetic stirrer (Matrex) and stirring was 
maintained at 100 rpm at 37°C with a thermostatic control. 
Samples were collected every half an hour over a period 
of five hours and assayed spectrophotometrically for drug 
content at 295.7 nm.
Results and discussion
Albendazole-encapsulated liposomes
Drug-encapsulated PEG-liposomes were prepared by the 
combination of PC:CH:PEG-PC in the ratio of 5:4:1. On 
the other hand, conventional liposomes were prepared 
by mixing PC:CH in the ratio of 6:4 and lipids were dis-
solved in methanol:chloroform solution taken in the ratio 
(1:1 V/V). TEM micrograph was taken at 20,000 and 25,000 
magnifications and clearly showed the formation of lipo-
somes of moderate sizes ranging 50 to 150 nm. (Figures 1a 
and 1b). Most of the liposomes formed appeared spherical or 
slightly asymmetrical in shape and were mainly unilamellar 
in arrangement.
Encapsulation efficiency
The absorbance at different concentration of albenda-
zole was measured using a UV-vis spectrophotometer 
at 295.7 nm. The standard curve of the albendazole was 
made by plotting absorbance against the concentration 
(Figure 2). The absorbance is no longer linear at concentra-
tion 10–200 µg/mL and 400–500 µg/mL. The concentration 
of the nonencapsulated drug in the supernatant was deter-
mined using this curve. Consequently, the encapsulation 
efficiency of different types of liposomes entrapping alben-
dazole was easily calculated. The encapsulation efficacy was 
obtained as the mass ratio between the amount of the drug 
incorporated in liposomes and this ratio was used in the 
liposome preparation. By inspection of  Table 1, it is obvious 
that albendazole-encapsulation efficiency had higher val-
ues in cases of PEGylated liposomes than in conventional 
liposomes. The total drug used during the preparation of 
liposomes was 1 mL of 1 mM albendazole. So using the 
formula the encapsulation efficiency of non-PEGylated and 
albendazole-loaded PEGylated liposomes was found to be 
72% and 81%, respectively.
The highest encapsulation efficiency (81%) was observed 
with the PEGylated liposomes composed of PC:CH:PEG-PC 
(5:4:1) molar ratio. Liposomes prepared with PC:CH (7:2) 
molar ratio, showed the lowest encapsulation efficiency and 
were excluded from further studies.
Absorbance at various concentrations of albendazole was 
measured using a UV-vis spectrophotometer at 295.7 nm. The 
standard curve for each drug release was established using the 
Beer–Lambert equation, which correlates the extinction coef-
ficient (ε) of a substance with the absorbance (A): A = ε.c.b 
where: ε is extinction coefficient; c is concentration of solu-
tion (mol/L); b is thickness (cm).
stability study
PEGylated liposomes were selected and their physical and 
chemical stability was evaluated at three different temperatures 
for 3 months (Table 2). Initially, the mean vesicle size was 
150 nm and encapsulation efficiency was 81%, no significant 
changes in drug encapsulation efficiency was observed during 
the course of stability study for formulations stored at −20°C 
and 4°C (P  0.05) but there was a significant decrease in 
albendazole encapsulation efficiency for liposomes stored at 
room temperature (P  0.05). The mean vesicle size showed 
an increase at all storage temperatures (P  0.05) while par-
ticle size of the formulations was increased up to fourfold 
after three months at room temperature. This extraordinary 
increase in the particle size of liposomes may be due to the 
aggregation or swelling of liposomes. Further experiments are 
required to explain this phenomenon. Results of the stability 
study are shown in (Figure 3).International Journal of Nanomedicine 2010:5 104
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Figure 1 Transmission electron microscopic photograph of liposome A) Albendazole-loaded non-Pegylated or conventional liposomes and B) Albendazole-loaded Pegylated liposomes.International Journal of Nanomedicine 2010:5 105
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In vitro release studies
Evaluation of in vitro drug release from encapsulated 
liposome was done by dialysis method. The output obtained 
by the dialysis method provided a correlation with the 
in vivo release.26 The in vitro release behavior of the free 
albendazole, albendazole-loaded conventional liposomes, 
and PEGylated liposomes, is summarized in the cumulative 
percentage release shown in Figure 4. For the measurement of 
release rate of the free albendazole, and from the liposomes 
both PEG coated and uncoated, was measured at 37°C in 
PBS containing 7% (V/V) PEG and 25% (V/V) methanol. 
Over a period of five hours the measurement was taken after 
every half an hour at 295.7 nm. The value of concentration 
corresponding to the absorbance was calculated from the 
albendazole standard curve. The drug release rate of con-
ventional liposomes and PEGylated liposomes or stealth 
liposomes is often comparable.
The release rate of the drug was highest for the free 
drug while the rate of release from PEG liposomes was less 
than that of conventional liposomes. It seems that by add-
ing PEG to the liposomes, the release rate of drug from the 
liposomes may decrease in its values. This confirms the fact 
that PEG acts as a barrier against diffusion of hydrophilic 
drugs. The hydrophobic long alkyl chains of the polymer 
may act as a barrier and the drug was effectively entrapped 
in the polymers.
Discussion
Among a variety of targeted drug carrier systems, liposomes 
have been studied extensively because of their capability to 
accommodate a large variety of drugs, alongside their good 
biocompatibility, low toxicity, and lack of immune system 
activation or suppression.27
The present study was designed to develop and compare 
albendazole containing nanovesicular conventional and 
PEGylated liposomes. Comparing the results of both con-
ventional and PEGylated liposomal formulations of the same 
composition and molar ratio, it is obvious that PEGylated 
liposomes showed a more sustained action owing to the 
presence of PEGcoating on the surface, which release the 
drug slowly over a prolonged period of time. It is to be noted 
that the in vitro release results are consistent with those of 
the encapsulation efficiency, as the PEGylated liposomes 
with the highest cholesterol content PC:CH:PEG-PC (5:4:1) 
molar ratio and the highest encapsulation efficiency (ie, low 
leakage ability) showed the lowest drug release percentage. 
There was no significant difference between stability results 
of the liposome storage at 4°C or −20°C. The results of the 
stability study revealed that the prepared liposomes are stable 
for more than three months’ storage at 4°C or −20°C. This 
extraordinary increase in the particle size of liposomes at 
room temperature may be due to the aggregation or swelling 
of liposomes
As a rule of thumb, the drug concentration in the 
sink phase in release experiments should be kept below 
10% saturation. If the drug is poorly soluble in water, 
nonaqueous solvents or solubilizing agents may be 
added to the sink. In case of albendazole-encapsulated 
liposomes, a release medium containing 7% (V/V) PEG 
and 25% (V/V) methanol was employed to provide sink 
conditions. The reproducibility and efficacy of the release 
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Figure 2 The standard curve of Albendazole drug at 295.7 nm.
Table 1 Encapsulation efficiency of liposomes
S no Type of liposomes Liposomal formulation 
composition (molar ratio)
Liposomal formulation 
charge
Encapsulation 
efficiency
1 conventional  
liposomes
Pc:ch (6:4)  
Pc:ch (7:2)
Neutral  
Neutral
72%  
50%
2 Peg-liposomes Pc:ch:Peg-Pc (5:4:1)  
Pc:ch:Peg-Pc (6:2:1)
Neutral  
Neutral
81%  
65% 
Abbreviations: Pc, phosphatidylcholine; ch, cholesterol; Peg, polyethylene glycol.International Journal of Nanomedicine 2010:5 106
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Table 2 Particle size of albendazole-loaded conventional and Pegylated liposomes mean size (nm)
Liposomal formulation 
composition (molar ratio)
Liposomal formulation 
charge
Freshly  
prepared
4°C After three months 
−20°C Room temperature
Pc:ch (6:4)  
Pc:ch (7:2)
Neutral 
Neutral
153 ± 6.4
141 ± 5.2
160 ± 8.7
155 ± 7.1
173 ± 9.5
160 ± 7.9
425 ± 19.69
397 ± 17.2
Pc:ch:Peg-Pc (5:4:1) Neutral 145 ± 5.5 157 ± 7.6 171 ± 9.3 432 ± 20.35
Pc:ch:Peg-Pc (6:2:1) Neutral 162 ± 8.5 176 ± 9.4 184 ± 10.3 450 ± 25.1
Abbreviations: Pc, phosphatidylcholine; ch, cholesterol; Peg, polyethylene glycol.
study were ensured through a control sample containing 
drug in the free form. This could ensure that the dialysis 
membrane was not a barrier throughout the release study. 
The free albendazole (control sample) was released in 
about two hours.
The in vitro release behavior of free albendazole, albenda-
zole-loaded conventional liposomes and PEGylated liposomes 
was summarized. In case of free albendazole more than 80% 
drug was released within the first sampling time (30 minutes) 
while both liposomal formulations produced an initial slower 
effect in which albendazole release was more than 25% for 
PEGylated and 35% for non-PEGylated liposomes within the 
first sampling time (30 minutes). The literature reports that drug 
release profiles from liposomes characteristically show an initial 
fast drug loss followed by slower rates of drug loss.28,29 The initial 
fast rate of release is commonly ascribed to drug detachment 
from liposomal surface while the later slow release results from 
sustained drug release from the inner lamellae. Albendazole 
is mainly associated within the bilayer lipid structure of the 
liposomes. The in vitro release study of albendazole showed no 
burst effect so that the drug transport out of the liposomes was 
driven mainly by a diffusion-controlled mechanism. The slight 
deviation at 210 minutes seems to be the effect of agglomera-
tion of more PEG over liposome surface after a particular time 
interval which reshuffles soon it self due to intermolecular 
interaction with the surrounding environment.
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Figure 3 Albendazole encapsulated Pegylated liposomes stability after 3 months storage at three different temperatures.
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Compared to the control data, albendazole release from 
PEGylated liposomes is prolonged. The slower release in 
PEGylated liposomes could be because of the fast hydration 
process at presenting the PEG on the surface of the particles. 
This result suggests that it takes time for albendazole to be 
released once encapsulated in the liposomes because lipid 
bilayer is stabilized by cholesterol. Thus a depot effect could be 
achieved using liposomes, especially in the PEGylated liposo-
mal formulation. The above results, which suggest that the drug 
would be stable in the blood circulation and would be released 
slowly at the target site, are indications that our PEGylated 
liposomal formulation meets the requirements for an effective 
drug delivery system.30 Also the drug release data confirmed 
the drug entrapment efficiency results determined.
Conclusion
Evaluation of in the vitro release profile of hydrophobic drugs 
from liposomal formulations could be problematic. But this 
could be manipulated through employment of a proper release 
medium that could provide sufficient sink conditions without 
affecting the stability of the liposomal formulation. The results 
suggest that albendazole released for a prolonged period of 
time from the PEGylated liposomal formulations. Since they 
had nanodimensions, longer residence time in systemic circu-
lation could help them reaching the target tissues. Nanosized 
PEGylated liposomes, would be a promising delivery systems 
for albendazole in the treatment of hydatid cyst. However, 
further studies including in vivo experiments are warranted.
Acknowledgments
The authors thank the technical support provided by State 
Biotechnology Programme, Biotech Bhawan, Haldi-263146, 
Uttarakhand. The authors also thank the Directorate of 
Research, G.B. Pant University of Agriculture and Technology, 
Pantnagar for providing laboratory facilities and Dr Rajendra 
Dobhal, Advisor, State Biotechnology Programme, Biotech 
Bhawan, Haldi-263146, Uttarakhand. The authors report no 
conflicts of interest in this work.
References
  1.  Bangham AD, Standish MM, Miller N. Cation permeability of 
phospholipid model membranes: effect of narcotics. Nature. 
1965;208:1295–1297.
  2.  Anabousi S, Laue M, Lehr CM, Bakowsky U, Ehrhardt C. Assessing 
transferrin modification of liposomes by atomic force microscopy 
and transmission electron microscopy. Eur J Pharm Biopharm. 
2005;60:295–303.
  3.  Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, 
Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 
2005;391:71–97.
  4.  Vyas SP, Quraishi S, Gupta S, Jaganathan KS. Aerosolized liposome-
based delivery of amphotericin B to alveolar macrophages. Int J Pharm. 
2005;296:2–25.
  5.  Iinuma H, Maruyama K, Okinaga K, et al. Intracellular targeting 
therapy of cisplatin-encapsulated transferring-polyethyleneglycol 
liposome on peritoneal dissemination of gastric cancer. Int J Cancer. 
2002;99:130–137.
  6.  Hong RJ, Tseng YL. Phase I and pharmacokinetic study of a stable, 
polyethylene-glycolated liposomal doxorubicin in partients with solid 
tumors. Cancer. 2001;91:1826–1833.
  7.  Oku N, Doi K, Namba Y, Okada S. Therapeutic effect of adriamycin 
encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing 
mice. Int J Cancer. 1994;58:415–419.
  8.  Tokudome Y, Oku N, Doi K, Namba Y, Okada S. Antitumor activity 
of vincristin encapsulated in glucuronide-modified long-circulating 
liposomes in mice bearing Meth A sarcoma. Biochim Biophys Acta. 
1996;1279:70–74.
  9.  AllenTM, Stuart DD. Liposomal pharmacokinetics. Classical, sterically-
stabilized, cationic liposomes and immunoliposomes. In: Janoff AS, 
editor. Liposomes: Rational design. New York, NY: Marcel Dekker, 
Inc; 2005. pp. 63–87.
10.  Working PK, Newman MS, Stuart Y, et al. Pharmacokinetics, bio-
distribution and therapeutic efficacy of doxorubicin encapsulated in 
STEALTH liposomes. J Liposome Res. 1994;46:667–687.
11.  Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. 
Comparative sencapsulated in long-circulating, pegylated liposomes 
(SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 
1999;43:1–7.
12.  Budai L, Hajdu M, Budai M, et al. Gels and liposomes in optimized 
ocular drug delivery: Studies on ciprofloxacin formulations. Int J 
Pharm. 2007;343:34–40.
13.  Vyas SP, Rawat M, Rawat A, Mahor S, Gupta PN. Pegylated protein 
encapsulated multivesicular liposomes: a novel approach for sustained 
release of Interferon α. Drug Dev Ind Pharm. 2006;32:699–707.
14.  Han HD, Lee A, Hwang T, et al. Enhanced circulation time and 
antitumor activity of doxorubicin by comblike polymer-incorporated 
liposomes. J Control Release. 2007;120:161–168.
15.  Davis A, Dixon H, Pawlowski ZS. Multicentre clinical trials of 
benzimidazole-carbamates in human cystic echinococcosis (phase 2). 
Bull World Health Organ. 1989;67:503–508.
16.  Horton RJ. Albendazole in treatment of human cystic echinococcosis: 
12 years of experience. Acta Trop. 1997;64:79–93.
17.  Jung H, Medina L, Garcia L, Fuentes I, Moreno-Esparza R. Absorption 
studies of albendazole and some physicochemical properties of the 
drug and its metabolite albendazole sulphoxide. J Pharm Pharmacol. 
1998;50:43–48.
100
90
80
70
60
50
40
30
20
10
0
0 30 60 90 120 150 180 210 240 270
Drug release from
Drug release from
liposomes
PEG liposomes
Free drug
Time (in minutes)
%
 
D
r
u
g
 
r
e
l
e
a
s
e
d
In vitro drug release
Figure 4 In vitro release curve of albendazole -loaded non-Pegylated, Pegylated 
liposomes and free drug in phosphate buffer at 37°c.International Journal of Nanomedicine 2010:5
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
108
Panwar et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
18.  Hardin TC, Najvar LK, Rizzo J, Fothergill AW, Rinaldi MG, Graybill JR. 
Discrepancy between in vitro and in vivo antifungal activity of albendazole. 
J Med Vet Mycol. 1998;35:153–158.
19.  Ramos G, Orduna A, Garcia-Yuste M. Hydatid cyst of the lung: diagnosis 
and treatment. World J Surg. 2001;25:46–57.
20.  Anadol D, Ozcelik U, Kiper N, Gocmen A. Treatment of hydatid disease. 
Paediatr Drugs. 2001;3:123–135.
21.  Keshmiri M, Baharvahdat H, Fattahi SH, Davachi B, Dabiri RH, 
Baradaran H. Albendazole versus placebo in treatment of echinococ-
cosis. Trans R Soc Trop Med Hyg. 2001;95:190–194.
22.  Alexander M, Biren PM, Daniel TC, Owe O, Richard NZ. Rapid 
preparation of giant unilamellar vesicles. Proc Natl Acad Sci U S A. 
1996;93:11443–11447.
23.  Law SL, Shih CL. Characterization of calcitonin-containing 
liposomes formulations for intranasal delivery. J Microencapsul. 
2001;18:211–221.
24.  Gulati M, Grover M, Singh M, Singh S. Study of azathioprine encap-
sulation into liposomes. J Microencapsul. 1998;15:485–494.
25.  Zhang JA, Anyarambhatla G, Ma L, et al. Development and charac-
terization of a novel Cremophor EL free liposome-based paclitaxel 
(LEPETU) formulation. Eur J Pharm Biopharm. 2005;59:177–187.
26.  Woo BH, Kostanski JW, Gebrekidan S, et al. Preparation characterization 
and in vivo evaluation of 120-day poly (D,L-lactide) leuprolide microspheres. 
J Control Release. 2001;75:307–315.
27.  Metselaar JM, Mastrobattista E, Storm G. Liposomes for I.V. 
drug targeting: Design and applications. Mini Rev Med Chem. 
2002;2:319–329.
28.  Henriksen I, Sande SA, Smistad G, Agren T, Karlsen J. In vitro 
evaluation of drug release kinetics from liposomes by fractional dialysis. 
Int J Pharm. 1995;119:231–238.
29.  Paveli Z, Kalko Basnet N, Schubert R. Liposomal gels for vaginal drug 
delivery. Int J Pharm. 2001;219:139–149.
30.  Song H, Zhang J, Han Z, et al. Pharmacokinetic and cytotoxic studies 
of pegylated liposomal daunorubicin. Cancer Chemother Pharmacol. 
2006;57:591–598.